New Delhi (NVI): US Pharma giant Pfizer today said that its coronavirus vaccine developed with German partner BioNTech is 95 per cent effective and that the phase 3 study of its Covid vaccine candidate has met all primary efficacy endpoints.
The US and German biotech firms are collaborating on the project. Pfizer came up with the results after administering the vaccine candidate BNT162b2 to 170 coronavirus cases and demonstrated 95% efficacy beginning 28 days after the first dose.
In a series of tweets, Pfizer said that the safety milestone required by the US FDA (Food and Drug Administration) for Emergency Use Authorization (EUA) has been achieved. “To date, no serious safety concerns related to the vaccine candidate have been reported,” it said.
BREAKING: We are proud to announce, along with @BioNTech_Group, that the Phase 3 study of our #COVID19 vaccine candidate has met all primary efficacy endpoints.
— Pfizer Inc. (@pfizer) November 18, 2020
The pharmaceutical company further said that within days, it plans to submit a request to the US FDA for an EUA based on the totality of safety and efficacy data collected, as well as manufacturing data relating to the quality and consistency of the vaccine candidate.
“We also plan to submit the efficacy and safety data from the study for peer-review in a scientific journal once analysis of the data is completed,” the company said.
On Monday, another US based bioechnology company, Moderna had said that the Covid vaccine developed by it is 94.5 per cent effective at preventing coronavirus.
-ARK
